Related Experiment Video
Updated: Jun 23, 2026

Methods for the Determination of Rates of Glucose and Fatty Acid Oxidation in the Isolated Working Rat Heart
Published on: September 28, 2016
Metabolic mechanisms in heart failure
Houman Ashrafian1, Michael P Frenneaux, Lionel H Opie
1Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK. houman.ashrafian@cardiov.ox.ac.uk
Insights
Heart failure can worsen metabolism and insulin resistance, creating a harmful cycle. New therapies targeting these metabolic changes may improve heart function and reduce mortality.
Area of Science:
- Cardiology
- Metabolic Medicine
- Biochemistry
Background:
- Neurohumoral antagonism has improved heart failure outcomes but residual mortality remains high.
- Heart failure is linked to metabolic abnormalities, including insulin resistance, potentially driven by neurohumoral activation.
- A detrimental cycle of heart failure promoting metabolic changes, which in turn worsen heart failure, is hypothesized.
Purpose of the Study:
- To review the cellular mechanisms and pathophysiology of altered metabolism and insulin resistance in heart failure.
- To explore how these metabolic changes contribute to the progression of heart failure.
- To discuss current and novel therapeutic strategies targeting metabolic dysfunction in heart failure.
Main Methods:
- Review of existing literature on myocardial metabolism, insulin resistance, and heart failure pathophysiology.
- Analysis of cellular mechanisms linking neurohumoral activation to metabolic perturbations.
- Discussion of therapeutic interventions aimed at mitigating aberrant metabolism.
Main Results:
- Heart failure can induce insulin resistance and alter myocardial substrate utilization, favoring free fatty acid over glucose metabolism.
- These metabolic changes lead to reduced myocardial energy (ATP, phosphocreatine) and impaired mechanical efficiency.
- Neurohumoral activation, adverse fatty acid metabolism, and insulin resistance are key contributors to myocardial energetic deficits.
Conclusions:
- Altered myocardial metabolism and insulin resistance represent a critical, self-perpetuating aspect of heart failure progression.
- Therapies including neurohumoral antagonism, lifestyle modifications, and novel metabolic modulators show promise.
- Targeting metabolic pathways offers a potential strategy to further reduce mortality and improve cardiac function in heart failure patients.
Abstract:
Although neurohumoral antagonism has successfully reduced heart failure morbidity and mortality, the residual disability and death rate remains unacceptably high. Though abnormalities of myocardial metabolism are associated with heart failure, recent data suggest that heart failure may itself promote metabolic changes such as insulin resistance, in part through neurohumoral activation. A detrimental self-perpetuating cycle (heart failure --> altered metabolism --> heart failure) that promotes the progression of heart failure may thus be postulated. Accordingly, we review the cellular mechanisms and pathophysiology of altered metabolism and insulin resistance in heart failure. It is hypothesized that the ensuing detrimental myocardial energetic perturbations result from neurohumoral activation, increased adverse free fatty acid metabolism, decreased protective glucose metabolism, and in some cases insulin resistance. The result is depletion of myocardial ATP, phosphocreatine, and creatine kinase with decreased efficiency of mechanical work. On the basis of the mechanisms outlined, appropriate therapies to mitigate aberrant metabolism include intense neurohumoral antagonism, limitation of diuretics, correction of hypokalemia, exercise, and diet. We also discuss more novel mechanistic-based therapies to ameliorate metabolism and insulin resistance in heart failure. For example, metabolic modulators may optimize myocardial substrate utilization to improve cardiac function and exercise performance beyond standard care. The ultimate success of metabolic-based therapy will be manifest by its capacity further to lessen the residual mortality in heart failure.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure I: Introduction
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management

